CG Oncology (CGON) Profit After Tax (2023 - 2026)
CG Oncology's (CGON) quarterly Profit After Tax came in at -$60.2 million in Q1 2026, down 74.74% YoY from -$238.3 million in Q1 2025, and down 45.72% on a QoQ basis from -$41.3 million in Q4 2025.
CG Oncology (CGON) Profit After Tax (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Profit After Tax data on file, last reported at -$60.2 million in Q1 2026.
- Quarterly Profit After Tax fell 74.74% year-over-year to -$60.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$186.8 million (down 76.92% YoY) and the FY2025 annual result came in at -$161.0 million, down 82.87% from the prior year.
- Profit After Tax slipped to -$60.2 million in Q1 2026, from -$41.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$8.7 million in Q1 2023 to a low of -$60.2 million in Q1 2026.
- A 4-year average of -$27.5 million and a median of -$20.4 million in 2024 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 29.93% in 2025, down 119.16% in 2025.
- Tracing CGON's Profit After Tax over 4 years: stood at -$16.6 million in 2023, then tumbled by 92.07% to -$31.8 million in 2024, then retreated by 29.93% to -$41.3 million in 2025, then tumbled by 45.72% to -$60.2 million in 2026.
- The last three Profit After Tax figures came in at -$60.2 million (Q1 2026), -$41.3 million (Q4 2025), and -$43.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | -79.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.10 Mn |
| Mar 31, 2026 | -60.20 Mn |
| Dec 31, 2025 | -41.31 Mn |
| Sep 30, 2025 | -43.81 Mn |
| Jun 30, 2025 | -41.43 Mn |
| Mar 31, 2025 | -34.45 Mn |
| Dec 31, 2024 | -31.80 Mn |
| Sep 30, 2024 | -20.41 Mn |
| Jun 30, 2024 | -18.90 Mn |
| Mar 31, 2024 | -16.93 Mn |
| Dec 31, 2023 | -16.56 Mn |
| Sep 30, 2023 | -11.77 Mn |
| Jun 30, 2023 | -11.61 Mn |
| Mar 31, 2023 | -8.67 Mn |